Exelixis, Inc. (EXEL)
Develops cancer medicines that target specific proteins driving tumor growth.
$56.51+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+51.7%
The outlook
Exelixis trades at $56.51 with analyst consensus leaning toward Buy, though the average price target sits roughly 8% below the current price. The stock is trading near its 52-week highs and above its key moving averages, signaling upward price momentum in recent months. The trailing P/E of 18.7 reflects moderate valuation relative to current earnings.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 15 analysts
Price trendAbove its 50- & 200-day averages
52-week range96% of the way from its 52-week low to high
Price targetAvg target -8% vs current price
Analyst price target
~12-month · 15 analysts$52.07average target-7.9% vs now
Now $56.51
Low $41.00High $64.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$14.20B
52-wk high
$57.57
52-wk low
$33.76
50-day avg
$53.14
200-day avg
$45.45
Trailing P/E
18.7